BGF led the round with participation from 24Haymarket to support US expansion and site growth.
"Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth."
The investment round was led by Archangels, with co-investment from Par Equity, Techstart Ventures, and ESM Investments.
"We are very pleased to have the continued support of our seed investors who have helped us shape and scale this revolutionary business from an idea to commercial launch ready. With this latest round of investment, we are scaling up commercialisation and production of Gii. We have now successfully launched our first product, Gii-Sens, into our beachhead market of Human Diagnostic Biosensors. Ultimately, this funding round will enable us to capitalise on being first to market world-wide with high performing, cost effective, application-specific 3D Graphene Foam, enabling better products."
The financing round was co-led by Tencent and Legal & General to support international expansion and product development.
"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."
The funding round was led by Atomico with participation from Lux Capital, Obvious Ventures, Kindred Capital and Inovia Capital.
"To add a fund of Atomico’s calibre and reputation to our investor base is a huge win for LabGenius. Atomico’s operational experience is second to none and they are the perfect partner to help us scale a global company from Europe. In addition, the confidence that Lux, Obvious, Kindred and Inovia have demonstrated in doubling down in this round reflects the tremendous technical progress that the team has made over the past 12 months."
Granpool Innovative Investments and Environmental Technologies Fund backed the round, which will support global expansion and technology development.
"The microbiome is a megatrend that is evolving very quickly, and we are the forefront of associated discovery with our unique solution to address the enterprise data challenge. We have our sights set too on other complex data challenges including CRISPR and quantum biological challenges, such as understanding the immune response more fully. The potential is phenomenal, and we are immensely grateful to our supporters for sharing our vision and helping us to scale at this pivotal time."
